Ginsburg Drugs And Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-12-2024
- Paid Up Capital ₹ 1.00 M
as on 04-12-2024
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.10 M
as on 04-12-2024
- Revenue 9.90%
(FY 2017)
- Profit 3.59%
(FY 2017)
- Ebitda -28.22%
(FY 2017)
- Net Worth 6.55%
(FY 2017)
- Total Assets 15.09%
(FY 2017)
About Ginsburg Drugs And Formulations
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.10 M.
Shanti Rao, Avnish Rao, and Vasu Rao serve as directors at the Company.
- CIN/LLPIN
U24232UP2004PTC029153
- Company No.
029153
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Gorakhpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ginsburg Drugs And Formulations Private Limited offer?
Ginsburg Drugs And Formulations Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Pharmaceutical Medicine, Gastrointestinal Drugs, Lactic Acid Bacillus Tablets, Antibacterial Drugs, Antibiotic Medicine, Antipyretic Medication, Paracetamol Tablets, Laptops.
Who are the key members and board of directors at Ginsburg Drugs And Formulations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanti Rao  | Director | 11-Oct-2004 | Current |
| Avnish Rao | Director | 19-Jan-2024 | Current |
| Vasu Rao | Director | 24-Feb-2024 | Current |
Financial Performance of Ginsburg Drugs And Formulations.
Ginsburg Drugs And Formulations Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 9.9% increase. The company also saw a slight improvement in profitability, with a 3.59% increase in profit. The company's net worth moved up by a moderate rise of 6.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ginsburg Drugs And Formulations?
In 2017, Ginsburg Drugs And Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Jul 2020 | ₹3.60 M | Open |
Allahabd Bank Creation Date: 28 Feb 2013 | ₹1.50 M | Open |
How Many Employees Work at Ginsburg Drugs And Formulations?
Unlock and access historical data on people associated with Ginsburg Drugs And Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ginsburg Drugs And Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ginsburg Drugs And Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
